Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DB26FSU96
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $82,042
Award facts
- Contract value 100% obligated
- $82,041.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $82,041.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 ml vials. This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract vehicle established on November 13, 2025, that authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical products to support Department of Defense healthcare operations.
The PPV-G GEN V represents a component of the broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders encompassing oncology treatments, biologics, vaccines, and specialty pharmaceuticals positions it as a critical supplier within the federal military medical supply chain. The contract structure, spanning a 30-month base period with three 30-month option periods through December 31, 2036, establishes DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting recurring Department of Defense medical supply requirements globally. No subcontractor relationships were identified in the award documentation.
Quick answers
Who was awarded contract SPE2DB26FSU96?
SPE2DB26FSU96 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DB26FSU96 worth?
The government has obligated $82,042 on SPE2DB26FSU96.
Is contract SPE2DB26FSU96 an order under another contract?
Yes. SPE2DB26FSU96 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSU96 competed?
The extent of competition for SPE2DB26FSU96 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award